The role of goal-directed therapy in high-risk cardiac surgical patients has not been determined. This study sought to observe the effect of a postoperative standardised haemodynamic protocol (SHP) on the administration of fluid and vasoactive drugs after high-risk cardiac surgery. This was an interventional pilot study. In 2010 to 2011, the SHP was introduced to the ICU at Wellington Regional Hospital, Wellington, New Zealand, for the perioperative management of patients undergoing high-risk cardiac surgery. A pulmonary artery catheter was inserted in the patients in the study group and fluids and supportive medications were provided in the ICU according to a protocol that targeted a cardiac index ≥2 l/min/m 2 , mixed venous oxygen saturation ≥60% and a mean arterial pressure of 65 to 75 mmHg. Data from 40 consecutive high-risk cardiac surgical patients assigned to this protocol were compared with a matched cohort of 40 consecutive high-risk cardiac surgical patients receiving 'usual care' in 2009. Baseline characteristics were similar in the two groups. There was no significant difference in the duration of noradrenaline infusion in the SHP cohort compared to historical controls (median [IQR] 18.5 hours [31.63] versus 18 hours [18.3]; P=0.35), despite patients receiving more fluid in their first 12 hours in the ICU (mean 4687 ml [SD±2284 ml] versus 1889 ml [SD±1344 ml]; P <0.001). The SHP cohort had a higher rate of reintubation (4 in 37 [10.8%] versus 0 in 40 [0%]; P=0.049). The SHP delivered significantly more fluid, but did not reduce the duration of noradrenaline infusion, compared to usual care.
High-risk cardiac surgical patients typically receive intravenous fluids and vasopressors in the postoperative period. These therapies are not usually standardised. Although the majority of cardiac surgical patients have a straightforward postoperative course, approximately 10% require prolonged postoperative care and experience multiple organ dysfunction 1 .
Goal-directed therapy (GDT) has been promoted in many perioperative care settings and may improve outcomes in patients who are undergoing high-risk general surgery and cardiac surgery [2] [3] [4] [5] [6] . Despite this, the application of GDT in ICUs has not been widely adopted 4 and evidence in the high-risk cardiac surgical population is relatively limited 2 .
This study was designed to evaluate a goal-directed treatment protocol in a high-risk group of cardiac surgical patients in whom a pulmonary artery catheter (PAC) had been inserted. While the use of such devices is controversial [7] [8] [9] , they provide cardiac output data that can be included in GDT protocols to optimise perioperative haemodynamics. Because high-risk cardiac surgical patients are the most likely patients to have PACs in situ, they are a logical group to study cardiac output-based GDT protocols.
It was hypothesised that, by following a GDT protocol targeting commonly recognised physiological endpoints, the duration that patients required vasopressor support after highrisk cardiac surgery would be reduced, compared to usual care. It was also hypothesised that, by only delivering fluids to those patients deemed fluid responsive, any reduction in vasopressor support would not come at the cost of additional fluid administration. Duration of noradrenaline infusion frequently limits the discharge of cardiac surgical patients from the ICU and therefore influences intensive care bed availability.
Materials and methods
This research was approved by the Health and Disability Ethics Committee of New Zealand (Approval No.: CEN/10/ EXP12). Written informed consent was requested from those patients eligible to take part in the prospective cohort.
Study design and setting
The study was conducted at Wellington Regional Hospital, New Zealand, a 450-bed metropolitan tertiary referral centre. During 2010 and 2011, a study investigating the possible benefits of ischaemic preconditioning (IPC) in high-risk cardiac surgical patients was conducted in the study hospital 10 . In order to standardise postoperative care in the IPC study, a PAC was inserted in all patients and therapy was guided by the standardised haemodynamic protocol (SHP). The current study was a sub-study to the IPC study and provided an opportunity to measure any improvement in clinical outcomes from the SHP. It was a single-centre, interventional pilot study comparing a prospective cohort of 40 high-risk cardiac surgical patients from 2010 to 2011, with a retrospective cohort of 40 consecutive patients in 2009. The prospective cohort was the control group in the IPC study and was subjected to the SHP. The retrospective cohort received usual care.
The intervention
The SHP mandated the insertion of a PAC (Swan-Ganz CCOmbo CCO/SvO 2 , Edwards Lifesciences, Irvine, CA, USA) to guide therapy in the first 12 hours postoperatively. The protocol sequentially delivered fluids, vasopressors, inotropes and vasodilators to target a cardiac index (CI) ≥2 l/min/m 2 , a mixed venous oxygen saturation ≥60% and a mean arterial pressure of 65 to 75 mmHg. If any of these targets were not met in the first 12 hours after surgery, then haemodynamic management was dictated by the protocol until they were met. This stepwise protocol emphasised the delivery of fluids (Hartmann's solution [Fresenius Kabi, Bad Homburg, Hesse, Germany]) to volume responsive patients, until they were no longer volume responsive. A patient was deemed to be 'volume responsive' when their CI rose by more than 10% after a fluid bolus of 5 ml/kg rounded to the nearest 250 ml. Perioperative anaesthetic management was also standardised. A simplified summary of the protocol is outlined in Figure 1 and the full protocol can be found in Appendix 1. Transesophageal echocardiography was not routinely performed in the study unit and was not included in the SHP. 
Participants
Patients were considered to be high-risk if they underwent: 1) coronary artery bypass grafting in the setting of an ejection fraction <50%, 2) valve replacement and coronary artery bypass grafting, 3) mitral valve repair or replacement, 4) double or triple valve procedure or 5) redo operation.
High-risk cardiac surgical patients after 18 May 2010 were eligible to take part in the IPC study. Patients were ineligible to participate in the IPC study if they were <18 years of age, had known peripheral vascular disease affecting the upper limbs, required deep hypothermic circulatory arrest or were being considered for radial artery conduit harvesting. Forty consecutive control-group patients from the IPC were used as the prospective SHP study cohort.
To identify the usual-care cohort, the hospital ICU database was searched to identify patients who fulfilled the IPC study eligibility criteria. The list of patients was compiled in reverse chronological order from 31 May 2009. A period one year prior to the IPC study was chosen to avoid any influence on usual care which may have occurred during preparation for the commencement of the IPC study.
Outcomes
The primary endpoint for the study was the duration of noradrenaline infusion in the postoperative period. Secondary outcomes included the amount of intravenous fluid provided in the first 12 hours, the duration of mechanical ventilation in the ICU, the cumulative dose (in mg) of noradrenaline support in the first 24 hours, peak postoperative serum creatinine in the ICU, reintubation rate and the duration of ICU stay. In addition, the use of other pharmacologic and mechanical cardiovascular supports, the total volumes of postoperative bleeding, return to theatre rate and ICU mortality were recorded for the index ICU admission. The study unit did not routinely measure blood lactate postoperatively.
Data sources/measurement
The duration of noradrenaline infusion was defined as the time from commencement in the ICU until the time noradrenaline was ceased and did not require recommencement for four consecutive hours. The duration of mechanical ventilation was defined as the time from ICU admission until initial extubation. It did not include non-invasive ventilation times or any hours of ventilation occurring due to reintubation. ICU stay was defined as the time of admission to the time of discharge, or the time at which patients were eligible for discharge (extubated with a fraction of inspired oxygen requirement of less than 0.5 and off vasopressor support for greater than four hours), whichever came first. Data in the SHP cohort were recorded on a data collection sheet by a research nurse from information provided in the operating theatre and the ICU. Data from the retrospective cohort were recorded by the research physician from historical patient notes. It was standard practice in the usual care cohort to administer Plasma-Lyte (Baxter, Deerfield, IL, USA) as the resuscitation fluid; however, the type of fluid was not recorded in this cohort. The usual care cohort also allowed the use of colloids, such as 20% albumin (CSL, Parkville, Victoria) and Gelofusine (B. Braun, Melsungen, Hesse, Germany), however, their use was not common.
Study size
The sample size of this pilot study was dictated by the size of the IPC study, which was originally 40 patients in each cohort and later increased to 48 patients. This study used the original planned cohort size of 40 patients. This was a pilot study to determine treatment effect in a unique patient population and therefore a power calculation was not performed. Given the small sample size of this pilot study, the investigators acknowledged that the outcomes were unlikely to conclude a treatment effect.
Statistical methods
The primary statistical plan was to compare the durations of noradrenaline support in the ICU. Similar studies 1, 11, 12 revealed that these data are not normally distributed and the nonparametric Mann-Whitney U test was chosen to compare sample medians. Normally distributed data were compared by analysis of variance and categorical data was compared using the chi-squared test. Small-sample categorical data were 
Results

Participants
Between 18 May 2010 and 23 June 2011, 580 patients in the IPC study were screened for eligibility. Four hundred and eighty-four were excluded, mostly because they did not meet the eligibility criteria for high-risk cardiac surgery (n=388). Twenty-one declined to participate and 75 were excluded for other reasons. The remaining 96 patients were randomised to either the intervention or control group, with 48 patients in each group. The 40th patient in the control group for use in this study was enrolled on 10 May 2011.
For the retrospective cohort, 49 consecutive high-risk patients were screened using the local ICU database from 31 May 2009 backwards, in order to obtain 40 files that were suitable for use. Six files were not available and three patients were deemed not to be high-risk after further review. Table 1 shows that the baseline characteristics of the two groups were similar. PACs were used in only three patients in the usual-care cohort and were used universally in the SHP cohort, as dictated by the study protocol. The inclusion criteria produced a cohort of high-risk cardiac surgical patients with a mean EuroSCORE of 8.4 in the usual-care group and 6.6 in the SHP group (P=0.2). Table 2 shows the primary and secondary outcome results. There was no significant difference in the duration of noradrenaline infusion between the usual-care cohort and the SHP cohort. The SHP cohort received significantly more fluid in the first 12 hours postoperatively than the usual care cohort (4687±2284 ml versus 1189±1344 ml, P <0.001). The SHP cohort also had a higher rate of reintubation (4 in 37 [10.8%] versus 0 in 40 [0%], P=0.049).
Descriptive data
Outcome data
There was no significant difference in the amount of blood loss in the first 24 hours, serum creatinine or the return to theatre rate. One patient in the SHP cohort died in the ICU. The patient notes were reviewed by the investigators and fluid overload was not thought to have contributed to the death. Unfortunately, data for some variables in the IPC study were incomplete on the ICU flowchart and the cohort size (n) for that variable was reduced accordingly.
Discussion
We conducted a single centre before-and-after study to evaluate a GDT protocol for high risk cardiac surgery patients. Contrary to our a priori hypothesis, despite increasing the amount of intravenous fluid administered, our protocol did not reduce the duration of noradrenaline infusion and appeared to increase the risk of failed extubation.
A systematic review and meta-analysis of studies evaluating GDT in cardiac surgical patients suggests that protocolisation of postoperative haemodynamic management reduces the hospital length-of-stay and postoperative complication rate 2 . Hospital length-of-stay was not measured in the current study; however, there was no evidence of a reduction in measured postoperative complications (failed extubation rate, serum creatinine, return-to-theatre rate or amount of postoperative blood loss). In contrast to the current study, studies included in the previous meta-analysis tended to focus on a low-risk group of patients. Of the five studies included, one included patients only with normal left ventricular systolic function 13 , a second had a mean EuroSCORE of less than 2.5 14 and a third had a mean ejection fraction of greater than 60% 1 .
A study by Kapoor et al 11 specifically evaluated GDT in highrisk cardiac surgical patients (EuroSCORE ≥3). In addition to reporting reduced ICU and hospital length-of-stay, this study reported a significant reduction in duration of inotrope infusion and ventilator support, both of which were outcome measures in the current study. However, the mean duration of these supports (in both arms of the Kapoor et al study) were longer than in the usual care cohort of the current study, despite having a lower mean EuroSCORE (4.3 versus 8.4). In comparison to the Kapoor et al study, patients in the current study tended to have relatively straight forward postoperative courses. Despite being a high-risk group, the majority of patients in the usual-care cohort were extubated, off vasopressor support and ready to go to the ward less than 24 hours after their surgery.
The physiological targets used in this study were derived from consensus amongst staff, though they were quite modest when compared to the targets set in other GDT trials in the cardiac surgical setting. Polonen et al 1 targeted a mixed venous oxygen saturation >70% and Goepfert et al 12 targeted a CI >2.5 l/m 2 . However, the CI and mixed venous oxygen saturation targets used in the current study were also standard practice in the study unit at the time of the usual-care cohort. We know that relationships exist between these physiological targets and organ perfusion and mortality; however, the evidence for the 'ideal' targets is sparse. Additional markers of organ perfusion such as blood lactate 1, 15 , base excess and skin perfusion may also be important targets. Identifying the 'ideal' physiological targets and their values for different subgroups of patients is an area for future research.
In this study, the protocol design led to the delivery of almost four times more fluid in the SHP cohort than the usual-care cohort. The measure of volume responsiveness (CI rise of >10% in response to a fluid bolus) may have led to excessive fluid delivery. Other predictors of volume responsiveness such as pulse pressure variation, stroke volume variation and the straight leg raise do not require the actual administration of fluid and may minimise unwanted fluid delivery 15 . Strict adherence to the SHP, despite good evidence of organ perfusion, may have led to excessive fluid administration.
This pilot study provided an opportunity to measure the potential clinical benefit of a particular GDT haemodynamic protocol and a practice change in the study unit. The study design was simple and required few extra resources.
However, the study has several limitations attributable to the study design. The SHP cohort had several exclusion criteria and also required consent to be enrolled in the trial, giving rise to selection bias. Although the baseline characteristics of the groups were similar, the use of historical controls is inherently associated with bias and confounding. The time separation between the two groups allowed for changes in staffing and changes in practice that arise with the passage of time. In the lead up to the study, there was an increase in the use of PACs and a new blood product protocol was introduced in preparation for the IPC study. These were not thought to represent normal care and so study investigators chose a retrospective cohort one year prior to the IPC study to represent usual care in an attempt to reduce the risk of confounding.
The SHP cohort were enrolled in a randomised clinical trial and the usual-care cohort were not and may have received an intensity of care that is over and above usual care. The SHP patients were also subjected to standardised management in the intraoperative period, which may have influenced the results in the postoperative period.
There were some missing data in the SHP cohort. This was due to occasional incomplete information on the ICU bedside chart, which was unable to be accurately retrieved.
Although rare, the usual-care group may also have received colloids which may have affected fluid and vasopressor requirements.
This was a small single-centre study focusing on a subgroup of high-risk patients using a specific haemodynamic protocol. The results of this study may not be generalisable to all cardiac surgical patients.
Finally, transesophageal echocardiography was not commonly performed in the study unit and was not incorporated into the SHP. Transesophageal echocardiography is increasingly being used to guide management in the postoperative cardiac surgical setting and its early role in the haemodynamically unstable patient is increasingly acknowledged 16 .
Conclusion
Targeting fluid responsiveness based on a CI rise of 10% may give rise to the administration of a lot more fluid than standard care, without a measured improvement in outcome. It appears that fluid responsiveness per se does not necessarily equate to clinical hypovolaemia. In addition, giving fluid in this way may not necessarily reduce the duration of vasopressor support or time spent in intensive care and may cause harm. There was no identifiable benefit from the SHP and our results suggest that it might increase the risk of reintubation. The SHP was ceased as a result of this study.
Step 1: Assessment of volume responsiveness*
Step 2: Afterload reduction Step 4: Maintain adequate cardiac output † (should occur simultaneously with Step 3)
Step 5: Maintain adequate SvO 2 *A sustained rise in central venous pressure or pulmonary artery diastolic in response to fluid boluses usually indicates adequate volume resuscitation. If the patient develops new 'instability' and filling pressures have not dropped, it may be appropriate to omit Step 1 of the algorithm. A straight leg raise may give you an idea of the patient's volume responsiveness and may be performed at Step 1 if the patient is felt to be 'well filled'. †If the CI is >3.5 l/min/m 2 and the mixed venous oxygen saturation is adequate, positive inotropes (milrinone, adrenaline, dobutamine, dopamine) should be weaned. Milrinone can generally be ceased without weaning due to its long half-life. An intra-aortic balloon pump should be considered if adequate CI is not achieved with adequate fluid resuscitation and milrinone at 5 mcg/kg/min. Unexpected low cardiac output should be evaluated by echocardiography. Potential findings and suggested management are as follows: ‡milrinone infusion: milrinone 10 mg in 50 ml compatible IV fluid (0.2 mg/ml). Patients should be maintained in sinus rhythm at between 80 and 110 b/m. If the rate is <80 bpm, then DDD pacing is the preferred mode.
Maintenance fluid is D5W at 0.8 ml/kg/hr (rounded to the nearest 10 ml). ALL DOSING ON THIS PROTOCOL IS BASED ON THE PATIENT'S ACTUAL PRE-OPERATIVE BODY WEIGHT.
Cardiac anaesthesia protocol
Pre-op: 
